<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421823</url>
  </required_header>
  <id_info>
    <org_study_id>RDD 111</org_study_id>
    <nct_id>NCT01421823</nct_id>
  </id_info>
  <brief_title>A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDD Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDD Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect and safety of alpha agonist ointment on&#xD;
      fecal incontinence severity in patients with idiopathic fecal incontinence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blinded cross over study. Approximately 40 subjects will be participating in&#xD;
      this 4 weeks study. A screening visit will be used to determine eligibility for the study.&#xD;
      Patients found eligible will receive alpha agonist ointment or placebo ointment for 2 weeks.&#xD;
      This will be followed by a second 2 weeks treatment cycle in which:&#xD;
&#xD;
        -  patients previously treated with alpha agonist will be treated with placebo.&#xD;
&#xD;
        -  patients previously treated with placebo will be treated with alpha agonist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal Incontinence</measure>
    <time_frame>After 2 weeks of treatment</time_frame>
    <description>number of unwanted/unexpected bowel movements in the time period after use of alpha agonist ointment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Idiopathic Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>alpha agonist ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha agonist ointment</intervention_name>
    <description>2 weeks local treatment with alpha agonist ointment</description>
    <arm_group_label>alpha agonist ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 weeks local treatment with placebo ointment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
          -  Male or female subjects 18 to 65 years of age.&#xD;
&#xD;
          -  Fecal incontinence score over 8.&#xD;
&#xD;
          -  The patient is able to understand the treatment and is willing to comply with the&#xD;
             prescribed regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Has a clinically significant history or presence of any of the following conditions:&#xD;
&#xD;
          -  Known allergy to the API.&#xD;
&#xD;
          -  Porphyria.&#xD;
&#xD;
          -  Glaucoma.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Active or past history of cardiovascular or cerebrovascular disease including unstable&#xD;
             angina, myocardial infarction, transient ischemic attacks/stroke, clinically&#xD;
             significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;&#xD;
&#xD;
          -  Type 1 diabetes mellitus;&#xD;
&#xD;
          -  Insulin treated type 2 diabetes mellitus.&#xD;
&#xD;
          -  Renal insufficiency.&#xD;
&#xD;
          -  Liver insufficiency.&#xD;
&#xD;
          -  Malignant disease within 5 years of screening;&#xD;
&#xD;
          -  Has hypertension (sitting blood pressure over 140/90 mmHg at screening)&#xD;
&#xD;
          -  History of rectal surgery.&#xD;
&#xD;
          -  History of HIV, hepatitis B, hepatitis.&#xD;
&#xD;
          -  Has used, in the last four weeks, drugs that may affect blood coagulation, such as&#xD;
             Aspirin (at a dose above 250 mg/day), Warfarin, Sintrom, Enoxaparin, Nadroparin,&#xD;
             Heparin, Clopidogrel, Ticlopidine.&#xD;
&#xD;
          -  Use of tricyclic or monoamine-oxidase inhibitors.&#xD;
&#xD;
          -  Has upon physical examination a rectal deformation or signs of rectal disease such as&#xD;
             fissure, bleeding hemorrhoids, fistula., infection or space occupying lesion.&#xD;
&#xD;
          -  Unable to understand the use instruction for the ointment, as judged by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehiel Ziv, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RDD Pharma Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Proctology Clinic, Asaf Harofe Medical Center</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>August 21, 2011</study_first_submitted>
  <study_first_submitted_qc>August 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fecal Incontinence</keyword>
  <keyword>Alpha agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

